While the pathophysiology of defective glucagon counterregulation during treatment-induced hypoglycemia in T1D and advanced T2D remains unclear, mounting evidence suggests that the hypersecretion of inhibitory paracrine hormone, SST, may suppress counterregulatory glucagon secretion via SSTR2 expressed by α-cells. The gene discussed is SSTR2; the disease is type 1 diabetes mellitus.